Eli Lilly announced Wednesday that its experimental weight loss drug retatrutide delivered more than twice the weight loss results compared to the highest dose of Ozempic in a major clinical trial, marking a significant advancement in pharmaceutical treatments for obesity and diabetes.
Clinical Trial Results Show Dramatic Differences
The phase 3 clinical trial tracked more than 1,000 adults with type 2 diabetes over 80 weeks. Participants taking the 9mg dose of retatrutide lost an average of 44.3 pounds, while those on the 12mg dose lost 47.4 pounds. By comparison, participants taking Ozempic’s highest 2mg dose lost just 20.9 pounds during the same period. The drug also demonstrated superior cardiovascular benefits, improving cholesterol levels and blood pressure measurements in trial participants.
Beyond weight loss, retatrutide reduced A1C levels by 2.2 percent compared to 1.8 percent with Ozempic. A1C serves as a critical marker for diabetes risk and blood sugar control over time. These combined results suggest retatrutide could address multiple health concerns simultaneously for patients struggling with weight management and metabolic disorders.
How The Drug Works Differently
Retatrutide distinguishes itself through a unique three-hormone approach. The once-weekly injection mimics GLP-1, GIP, and glucagon, three separate hunger-regulating hormones in the human body. Current market options like Ozempic and Wegovy mimic only GLP-1, while Mounjaro and Zepbound mimic both GLP-1 and GIP. The addition of glucagon represents the key innovation, as this hormone promotes fat burning even during rest periods.
GLP-1 affects multiple systems including the brain, muscles, pancreas, stomach, and liver according to the National Institutes of Health. GIP helps regulate blood sugar by stimulating insulin production. The combination of all three hormones appears to create synergistic effects that surpass existing treatments in both weight reduction and metabolic improvements.
Timeline And Safety Warnings
Eli Lilly plans to submit retatrutide for Food and Drug Administration approval in early 2027. Novo Nordisk has a competing experimental drug called CagriSema that expects FDA approval by year’s end. Neither drug currently holds FDA approval, meaning any versions available online come from black market sources and should not be consumed, according to FDA warnings.
Currently approved options include Ozempic and Mounjaro for type 2 diabetes treatment, while Wegovy and Zepbound have FDA approval for treating overweight and obesity conditions. Health care providers should evaluate whether these medications suit individual patient needs, as prescription medications require professional medical guidance and monitoring for safe, effective use.
Sources
Abcnews: New weight loss drug retatrutide provides double the weight loss of Ozempic, Lilly says